Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Operating Leases (2019 - 2025)

Kiora Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $203798.0 for Q4 2025.

  • For Q4 2025, Operating Leases rose 502.69% year-over-year to $203798.0; the TTM value through Dec 2025 reached $203798.0, up 502.69%, while the annual FY2025 figure was $203798.0, 502.69% up from the prior year.
  • Operating Leases reached $203798.0 in Q4 2025 per KPRX's latest filing, down from $248239.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $430405.0 in Q2 2025 to a low of $3502.0 in Q3 2022.
  • Average Operating Leases over 5 years is $107372.7, with a median of $80379.5 recorded in 2023.
  • Peak YoY movement for Operating Leases: plummeted 96.94% in 2022, then skyrocketed 970.74% in 2025.
  • A 5-year view of Operating Leases shows it stood at $90566.0 in 2021, then tumbled by 96.13% to $3502.0 in 2022, then skyrocketed by 1608.22% to $59822.0 in 2023, then tumbled by 43.47% to $33815.0 in 2024, then soared by 502.69% to $203798.0 in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Operating Leases are $203798.0 (Q4 2025), $248239.0 (Q3 2025), and $430405.0 (Q2 2025).